Time to Ambulation After ProGlide Closure

NCT ID: NCT07179536

Last Updated: 2026-01-23

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 300 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-10-01
• Study Completion Date: 2026-03-30

Brief Summary

Transradial access has become the standard for coronary procedures due to fewer vascular complications and shorter bed rest, yet transfemoral access remains essential for complex peripheral interventions requiring larger sheaths and stronger support. Vascular closure devices (VCDs), particularly suture-mediated devices such as ProGlide, have improved femoral access by reducing hemostasis time, ambulation delay, and patient discomfort. Although early ambulation after ProGlide closure has been reported, current practice varies widely, and the relationship between ambulation timing and vascular complications remains unclear. This trial aims to evaluate the effect of different ambulation times after ProGlide closure in transfemoral peripheral angiography or intervention, with the goal of identifying the optimal time to ambulation that balances safety and efficiency.

Detailed Description

Transradial access has replaced transfemoral access as the mainstream approach for coronary angiography and intervention due to its lower incidence of vascular complications and shorter postoperative bed rest. In non-coronary endovascular interventions, radial access is also an attractive alternative. However, the traditional femoral approach retains irreplaceable advantages: it is easier for puncture and sheath insertion, accommodates sheaths ≥ 8F, allows the delivery of larger stents, provides better guiding catheter support, and reduces procedural difficulty and time.

In recent years, the widespread use of vascular closure devices (VCDs) has further improved the physician and patient experience of femoral access. Compared with manual compression, VCDs significantly reduce hemostasis time, shorten postoperative bed rest, and improve patient comfort and satisfaction. VCDs can be classified into four categories based on the closure mechanism: collagen plug, suture-mediated, disc-based, and metal clip. Although comparative studies among different VCDs are limited, the efficacy and safety of suture-mediated VCDs have been well demonstrated. ProGlide, as a representative of suture-mediated VCDs, is favored for large sheath compatibility, reliable hemostasis, and low vascular complication rates.

Evidence from Aravind Sekhar et al. showed that patients undergoing diagnostic coronary angiography via femoral access could ambulate early after ProGlide closure, which is a key driver for reducing hospitalization time, lowering costs, and improving patient satisfaction. While previous studies have reported the benefit of VCDs in shortening time to ambulation, the determination of ambulation time was largely empirical, ranging from 2 to 12 hours depending on operator experience. Currently, there is a lack of evidence regarding the association between ambulation time and vascular complications at the access site. This study aims to investigate the impact of different ambulation times after ProGlide closure in patients undergoing transfemoral peripheral angiography or endovascular intervention on vascular access site complications, in order to determine the optimal timing for ambulation.

Conditions

Femoral Access Site Closure; Ambulation; Vascular Access Complication; Vascular Access Site Management

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: NONE

Study Groups

Early Ambulation (2 hours)

Patients instructed to ambulate 2 hours after ProGlide femoral artery closure.

Group Type: EXPERIMENTAL

Ambulation after ProGlide Closure

Intervention Type: PROCEDURE

Ambulation time after femoral artery access site closure using the ProGlide vascular closure device was assigned to 2 hours, 6 hours, or 12 hours post-procedure.

Intermediate Ambulation (6 hours)

Patients instructed to ambulate 6 hours after ProGlide femoral artery closure.

Group Type: EXPERIMENTAL

Ambulation after ProGlide Closure

Intervention Type: PROCEDURE

Ambulation time after femoral artery access site closure using the ProGlide vascular closure device was assigned to 2 hours, 6 hours, or 12 hours post-procedure.

Late Ambulation (12 hours)

Patients instructed to ambulate 12 hours after femoral access site closure with ProGlide.

Group Type: EXPERIMENTAL

Ambulation after ProGlide Closure

Intervention Type: PROCEDURE

Ambulation time after femoral artery access site closure using the ProGlide vascular closure device was assigned to 2 hours, 6 hours, or 12 hours post-procedure.

Interventions

Ambulation after ProGlide Closure

Ambulation time after femoral artery access site closure using the ProGlide vascular closure device was assigned to 2 hours, 6 hours, or 12 hours post-procedure.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Scheduled for peripheral angiography or endovascular intervention via transfemoral access.
• Femoral artery puncture site located at the common femoral artery.
• Use of 6-8F vascular sheath.
• Hemostasis achieved with 6F ProGlide closure device (defined as no active bleeding, no hematoma formation, and no ischemia of the punctured limb after closure).
• Preoperative ankle-brachial index (ABI) > 0.9 on both sides.
• Conscious, cooperative, and with normal lower limb mobility.

Exclusion Criteria

• Undergoing carotid artery intervention.
• Femoral artery diameter < 5 mm, or effective lumen < 5 mm due to plaque burden.
• History of vascular complications at the puncture site.
• Abnormal cardiopulmonary function.
• Intraoperative platelet count < 80 × 10⁹/L, or use of thrombolytic agents.
• Cognitive impairment, uncooperative, or limited lower limb mobility.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Chinese Academy of Medical Sciences, Fuwai Hospital

OTHER

Sponsor Role: lead

Responsible Party

Hui DONG

professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Hui Dong, MD

Role: PRINCIPAL_INVESTIGATOR

Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College

Locations

Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, Beijing Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Hui Dong, MD

Role: CONTACT

donghui666@sina.com

86-010-88322385

Xiongjing Jiang, MD

Role: CONTACT

jiangxiongjing@163.com

86-010-88322387

Facility Contacts

Hui Dong, MD

Role: primary

donghui666@sina.com

86-010-88322385

Xiongjing Jiang, MD

Role: backup

jiangxiongjing@163.com

86-010-88322387

Other Identifiers

2025-0906

Identifier Type: -

Identifier Source: org_study_id